Your new post is loading...
Matching Tumors With The Optimal Cancer Drugs
Science 2.0
The main driver of pancreatic cancer, a mutation in a gene called KRAS, has proven difficult to target with treatments.
Via Brian Shields
|
Rescooped by Ray and Terry's from Biomarkers and Personalized Medicine |
Scoop.it!
Via Brian Shields
Very Powereful Quote and an important one for clinicians to understand, " We have a small but effective inventory of 'druggable' mutations that we know play a role in cancer"